First data from the German Lipoprotein Apheresis Registry (GLAR)

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Health Services Research

Background:

• The German Federal Joint Committee (G-BA) has questioned reimbursement for procedures like lipoprotein apheresis.
• An interdisciplinary working group revised indications for lipoprotein apheresis based on current guidelines.
• A registry was proposed to provide data supporting lipoprotein apheresis for severe hyperlipidemic patients with progressive cardiovascular disease.

Purpose of the Study:

• To establish a German Lipoprotein Apheresis Registry (GLAR) to collect data on apheresis therapy.
• To align apheresis indications with current cardiovascular guidelines and reimbursement requirements.
• To provide evidence supporting the safety and efficacy of lipoprotein apheresis.

Main Methods:

• An interdisciplinary working group established indications for the registry in 2009.
• Financing was secured in 2011, and an internet-based registry was created.
• A pilot project concluded in 2012, and the registry became available to all German apheresis centers.

Main Results:

• The German Lipoprotein Apheresis Registry (GLAR) has been launched, with consensus among medical societies and health carriers.
• Initial data from GLAR support the safety of various apheresis treatment procedures.
• Early findings suggest potential effectiveness in preventing cardiovascular progression, complementing the Pro(a)LiFe-Study.

Conclusions:

• The establishment of the German Lipoprotein Apheresis Registry (GLAR) meets G-BA requirements.
• Preliminary GLAR data indicate the safety of apheresis treatments.
• Further research is necessary to statistically validate the observed effectiveness in preventing cardiovascular progression.